Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond - a podcast by Clinical Care Options
from 2020-08-14T21:00:08
::
::
In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:
- FLT3 inhibitors crenolanib and quizartinib
- Anti-CD47 antibody magrolimab
- IMGN632, a CD123 antibody–drug conjugate
- Anti-CD70 antibody cusatuzumab
- APR-246, targeting the TP53 mutation
Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.
Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options